KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
ZUG, Switzerland, April 05, 2016 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that Thomas Meyer, Ph.D., Chairman and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016, at 2:20 p.m. EDT from The Westin New York Grand Central hotel in New York City. The webcast will be available through the Events and Presentations page in the Investors section of the Company's website (www.aurismedical.com).
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
Company contact: Cindy McGee, Head of Investor Relations and Corporate Communications +41 61 201 1350, [email protected] Agency contact: Matthew P. Duffy, Managing Director, LifeSci Advisors 212-915-0685, [email protected]
